PBX1 and precursor B-cell acute lymphoblastic leukemia: Idelalisib is a promising treatment option for B-cell precursor acute lymphoblastic leukemia (BCP-ALL) patients with TCF3-PBX1 (E2A-PBX1), whereas other drugs could be useful depending on the genetic context of individual patients [67].